BB&T Corp Boosts Position in Novo Nordisk A/S (NVO)

BB&T Corp boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 14.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 128,300 shares of the company’s stock after buying an additional 16,202 shares during the quarter. BB&T Corp’s holdings in Novo Nordisk A/S were worth $6,177,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Proficio Capital Partners LLC raised its holdings in Novo Nordisk A/S by 6.1% during the 2nd quarter. Proficio Capital Partners LLC now owns 2,622 shares of the company’s stock worth $111,000 after purchasing an additional 150 shares during the last quarter. AlphaMark Advisors LLC raised its holdings in Novo Nordisk A/S by 1.1% during the 2nd quarter. AlphaMark Advisors LLC now owns 2,645 shares of the company’s stock worth $113,000 after purchasing an additional 30 shares during the last quarter. MUFG Americas Holdings Corp raised its holdings in Novo Nordisk A/S by 100.0% during the 2nd quarter. MUFG Americas Holdings Corp now owns 3,000 shares of the company’s stock worth $129,000 after purchasing an additional 1,500 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Novo Nordisk A/S by 167.8% during the 1st quarter. Tower Research Capital LLC TRC now owns 3,061 shares of the company’s stock worth $105,000 after purchasing an additional 1,918 shares during the last quarter. Finally, Cornerstone Advisors Inc. raised its holdings in Novo Nordisk A/S by 1,220.2% during the 2nd quarter. Cornerstone Advisors Inc. now owns 3,525 shares of the company’s stock worth $151,000 after purchasing an additional 3,258 shares during the last quarter. Institutional investors and hedge funds own 6.04% of the company’s stock.

Novo Nordisk A/S (NYSE NVO) traded up $0.78 during trading hours on Friday, hitting $49.91. 1,238,200 shares of the stock traded hands, compared to its average volume of 2,164,315. The company has a market cap of $125,281.50, a price-to-earnings ratio of 21.45, a P/E/G ratio of 2.93 and a beta of 0.63. Novo Nordisk A/S has a 12 month low of $30.89 and a 12 month high of $50.95.

Several research analysts have issued reports on the stock. BidaskClub upgraded shares of Novo Nordisk A/S from a “sell” rating to a “hold” rating in a report on Saturday, August 12th. BNP Paribas lowered shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a report on Monday, September 25th. Zacks Investment Research lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. Finally, Bank of America Corporation upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research note on Wednesday, September 6th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $55.00.

TRADEMARK VIOLATION WARNING: This story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/11/bbt-corp-has-6-18-million-stake-in-novo-nordisk-as-nvo.html.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply